MDXHealth
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
06 mrt 2007 - 21:42
Statutaire naam
MDXHealth
Titel
OncoMethylome Expands its Amsterdam Laboratory
Bericht
Liege (Belgium) – March 7, 2007, 8:00am CET – OncoMethylome Sciences (Euronext: ONCO) announced today that it has significantly expanded its Amsterdam laboratory operations. The expansion involved hiring of 10 additional scientists experienced in the field of molecular diagnostics, purchase of necessary molecular laboratory equipment, obtaining ISO laboratory certification, and leasing approximately 1000 m2 of laboratory space from the Academic Medical Center (AMC) in Amsterdam. The expansion was necessary to support OncoMethylome’s colorectal cancer program and to enhance its clinical trial testing services.
In the area of colorectal cancer, OncoMethylome is developing novel, non-invasive, molecular methylation tests to screen for colorectal cancer. The tests are performed on DNA isolated from stool or blood samples. The colorectal cancer program is concentrated in the company’s Amsterdam laboratory and is financially supported by the SenterNovem agency of the Dutch Ministry of Economic Affairs.
In the area of personalized treatment, OncoMethylome is developing tests that predict whether a drug treatment is likely to be effective for a specific patient. The expansion of the Amsterdam laboratory provides OncoMethylome with the required capacity and ISO certification for performing clinical trial testing services in-house.
Furthermore, the Amsterdam laboratory is foreseen to play an increasing role in facilitating OncoMethylome’s research collaborations with leading Dutch oncologists and medical research centers. The company’s current collaborators in the Netherlands include the Amsterdam VU Medical Center, the Research Institute Growth and Development (GROW) at the Maastricht Medical Center, and the University of Groningen.
Herman Spolders, CEO of OncoMethylome commented “Colorectal cancer screening tests and personalized treatment products are an important part of our product development pipeline. This expansion allows us to align our resources with our pro
Gerelateerde downloads
Datum laatste update: 25 februari 2026